Molecular Diagnostics Company, RedPath, Appoints Dennis M. Smith, Jr., M.D. as Chief Executive Officer
Pittsburgh, PA, February 8, 2011 – RedPath Integrated Pathology, Inc., a molecular diagnostics company dedicated to the effective diagnosis and treatment of cancer, today announced that it has named Dennis M. Smith, Jr., M.D., to serve as RedPath’s chief executive officer effective immediately. Smith replaces Mark Myslinski, who will continue to serve on the RedPath Board of Directors.
Smith brings over 30 years of experience in healthcare management, pathology, the outreach laboratory business, molecular diagnostics, laboratory medicine and blood banking. He is a board-certified clinical and anatomic pathologist and transfusion medicine specialist.
Smith’s professional career includes serving on the executive management team and board of directors of AmeriPath, Inc. (NASDAQ:PATH, acquired by Quest Diagnostics). While at AmeriPath, Smith’s positions included chief medical officer, executive vice-president of Genomic Strategies, and executive director of AmeriPath’s Center for Advanced Diagnostics. Smith has previously held board seats at Clarient, Inc. (NASDAQ: CLRT, acquired by General Electric), at Immucor, Inc. (NASDAQ: BLUD), the American Association of Blood Banks where he served as president, and the National Blood Foundation where he served as chairman. In the 1980s, Smith was executive head and director of blood services for the American Red Cross in Nashville, assistant professor of pathology at Vanderbilt and director of laboratories and chairman of the Department of Pathology at Memorial Hospital, Jacksonville, Florida, where he co-founded Memorial Laboratories, a successful outreach reference laboratory. Currently, Smith sits on the board of directors of RedPath Integrated Pathology, Inc., Jacksonville Country Day School and the Committee of Visitors for Vanderbilt University School of Engineering.
Brian G. Murphy, RedPath’s non-executive chairman and general partner of NewSpring Health Capital, commented that he looks forward to working with Smith in his new role. “Dr. Smith and I share a vision, which is to improve the lives of people with cancer by applying novel diagnostic tools to solve clinical patient management dilemmas,” he said.
Smith added, “I am very enthusiastic about RedPath’s future. Our positive Local Coverage Determination from Medicare that took effect late last year paves the way for rapid growth and adoption of our patented technology platform, PathFinderTG®. Both December and January produced record growth. I anticipate that this expansion will continue as our sales staff matures and pending clinical studies are published.”
About RedPath Integrated Pathology, Inc.
RedPath Integrated Pathology, Inc. is a genomics-based molecular diagnostics company that provides complex cancer diagnostic testing for pathologists, oncologists and clinicians. RedPath’s patented molecular-based platform, PathFinderTG®, allows molecular diagnostics to be integrated with routine pathology review of fixed slides, cytology and fluid specimens to render an earlier and more definitive diagnosis, improving patient outcomes and reducing healthcare costs. For more information about RedPath, please visit http://www.redpathip.com.